Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide

Neuro-Oncology

Volumn 12, Issue 9, 2010, Pages 917-927

  Bobustuc, George C ^a   Baker, Cheryl H ^a,b   Limaye, Arati ^a   Jenkins, Wayne D ^a   Pearl, Gary ^a   Avgeropoulos, Nicholas G ^a   Konduri, Santhi D ^a,b  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Gliomas; Levetiracetam; MGMT; MSin3A HDAC1; P53; Temozolomide

Indexed keywords

CARMUSTINE; ETIRACETAM; HISTONE DEACETYLASE 1; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHENOBARBITAL; PHENYTOIN; PROTEIN P53; TEMOZOLOMIDE; TRANSCRIPTION FACTOR SIN3A; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTE; CASE REPORT; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRANIOTOMY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME INHIBITION; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROPROTECTION; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; TRANSCRIPTION TERMINATION;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; PIRACETAM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 78650101872     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq044     Document Type: Article

References (33)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Burton EC, Prados M. Malignant gliomas. Curr Treat Options Oncol. 2000;1(5):459-468.
3. Erickson LC, Bradley MO, Ducore JM, Ewig RA, Kohn KW. DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas. Proc Natl Acad Sci USA. 1980; 77(1):467-471.
4. Erickson LC, Laurent G, Sharkey NA, Kohn KW. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature. 1980;288(5792):727-729.
5. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res. 2000;462(2-3):83-100.
6. Bobola MS, Berger MS, Silber JR. Contribution of O6-methylguanine- DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1- nitrosourea in human brain tumor-derived cell lines. Mol Carcinog. 1995;13(2):81-88.
7. Bobola MS, Blank A, Berger MS, Silber JR. Contribution of O6-methylguanine-DNA methyltransferase to monofunctional alkylating-agent resistance in human brain tumor-derived cell lines. Mol Carcinog. 1995;13(2):70-80.
8. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 1996;56(4):783-788.
9. Silber JR, Blank A, Bobola MS, et al. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res. 1999;5(4):807-814.
10. Tanaka S, Kobayashi I, Utsuki S, et al. O6-methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer. 2003;103(1):67-72.
11. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995;51:167-223.
12. Gerson SL, Willson JK. O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance. Hematol Oncol Clin North Am. 1995;9(2):431-450.
13. Grombacher T, Eichhorn U, Kaina B. p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene. 1998;17(7):845-851.
14. Harris LC, Remack JS, Houghton PJ, Brent TP. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res. 1996;56(9):2029-2032.
15. GuoW, Liu X, Lee S, Park NH. High O6-methylguanine methyl transferase activity is frequently found in human oral cancer cells with p53 inactivation. Int J Oncol. 1999;15(4):817-821.
16. Natsume A, Ishii D, Wakabayashi T, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005;65(17):7573-7579.
17. SilberJR, Blank A, Bobola MS, et al. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res. 1999;5(4):807-814.
18. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-1354.
19. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000;60(9):2368-2371.
20. Murphy M, Ahn J, Walker KK, et al. Transcriptional repression by wildtype p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 1999;13(19):2490-2501.
21. Suzuki H, Ouchida M, Yamamoto H, et al. Decreased expression of the SIN3A gene, a candidate tumor suppressor located at the prevalent allelic loss region 15q23 in non-small cell lung cancer. Lung Cancer. 2008;59(1):24-31.
22. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 2007;67(20): 9809-9816.
23. Biroccio A, Bufalo DD, Ricca A, et al. Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Ther. 1999;6(6):1064-1072.
24. Gong J, Ammanamanchi S, Ko TC, Brattain MG. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Cancer Res. 2003;63(12):3340-3346.
25. Liu W, Konduri SD, Bansal S, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem. 2006;281(15):9837-9840.
26. Sayeed A, Konduri SD, Liu W, et al. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 2007;67(16):7746-7755.
27. Ueda Y, Doi T, Takaki M, et al. Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy. Brain Res. 2009;1266:1-7.
28. Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46(suppl 9): 140-148.
29. Doheny HCRN, Whittington MA, Jefferys JG, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res. 1999;34(2-3): 161-168.
30. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia. 2007; 48(7):1351-1359.
31. Eyal S, Yagen B, Sobol E, et al. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia. 2004;45(7):737-744.
32. Nutt CL, Loktionova NA, Pegg AE, Chambers AF, Cairncross JG. O(6)-methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes. Carcinogenesis. 1999;20(12):2361-2365.
33. Srivenugopal KS, Shou J, Mullapudi SR, et al. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine- DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res. 2001; 7(5):1398-1409.